Skip to content

Effect of a Single Dose of Adenosine in Reduce Cancer-related Neuropathic Pain

The role of a Single Dose of Adenosine in Epidural Space in Reduction of neuropathic pain in patients with primitive neuroectodermal tumors

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017031428878N1
Enrollment
88
Registered
2017-05-14
Start date
2013-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer. Brain, unspecified

Interventions

Intervention 1: All patients in intervention group will be treated with a basic analgesia with acetaminophen (30 mg/kg/day) and fentanyl (1µg/kg/hour) by patient-controlled intravenous analgesia (PCIA
Treatment - Drugs
All patients in intervention group will be treated with a basic analgesia with acetaminophen (30 mg/kg/day) and fentanyl (1µg/kg/hour) by patient-controlled intravenous analgesia (PCIA) throughout the
All patients in control group will be treated with a basic analgesia with acetaminophen (30 mg/kg/day) and fentanyl (1µg/kg/hour) by patient-controlled intravenous analgesia (PCIA) throughout the stu

Sponsors

Mahak Hospital and Rehabilitation Complex
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 22 Years

Inclusion criteria

Inclusion criteria: criteria: presence of chronic neuropathic pain; failure to provide adequate pain relief with conventional treatments. Exclusion criteria: Caudaequina syndrome; Anticoagulation, coagulopathy and suspected local or systemic infection.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
Patient satisfaction. Timepoint: On days 1, 2, 3, 5, 7, 10 and 14 after injections, patient responses to treatments were evaluated. Method of measurement: questionnaire.;Adverse effect. Timepoint: On days 1, 2, 3, 5, 7, 10 and 14 after injections, patient responses to treatments were evaluated. Method of measurement: questionnaire.

Primary

MeasureTime frame
Pain. Timepoint: On days 1, 2, 3, 5, 7, 10 and 14 after injections, patient responses to treatments were evaluated. Method of measurement: questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Faranoush

Mahak

faranoush47@gmail.com allahverdy.maryam@yahoo.com shahverdi_ehsan@yahoo.com+98 21 2350 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 24, 2026